494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study

✍ Scribed by Severine Vermeire; Maria T. Abreu; Geert D'Haens; Jean-Frédéric Colombel; Krassimir Mitchev; Richard Fedorak; Andreas Raedler; William J. Sandborn; Paul J. Rutgeerts

• Book ID: 119428193
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 104 KB
• Volume: 134
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/s0016-5085(08)60318-2